PDAC · Pancreatic Ductal Adenocarcinoma
KRAS G12D/G12V Mutation STRONG
90% of PDAC driven by KRAS oncogenic mutation. First direct inhibitor MRTX1133 in Phase 1/2 2024. Target confirmed. Clinical benefit pending.
MRTX1133 · Mirati Therapeutics Phase 1/2 · 2024
Late Detection Sorry SORRY
85% diagnosed Stage III/IV — inoperable at presentation. No early detection test. CA19-9 specificity 80% at Stage IV but <30% sensitivity at Stage I. CancerSEEK ctDNA panel promising, not clinical.
Lennon et al. 2020 Science (CancerSEEK) · Tempero 2019 J Natl Compr Canc Netw
Immune Desert Sorry SORRY
Dense desmoplastic stroma excludes T cells. TMB-low, cold tumor phenotype. Every checkpoint inhibitor (anti-PD1, anti-CTLA4) failed uniformly in PDAC. CAR-T fails to infiltrate. Stroma remodeling is the unlock.
Feig et al. 2013 PNAS · Raphael et al. 2017 Cell (TCGA PDAC)
5-Year Survival 12% PROVEN
Grim reality: 12% 5yr survival overall. Surgery-eligible (20%): 20–25% 5yr. Metastatic: <3% 5yr. Most lethal solid tumor per life-years lost.
SEER Database 2023 · ACS Cancer Facts & Figures
T1D · Pancreatic Autoimmune
Beta Cell Destruction PROVEN
GAD65, IA-2, ZnT8 autoantibodies confirmed. Islet autoimmunity precedes clinical T1D by years. 3+ positive antibodies = near-certain T1D in 5yr.
Ziegler et al. 2013 NEJM (TrialNet) · Insel et al. 2015 Diabetologia
Teplizumab (anti-CD3) STRONG
FDA approved Nov 2022. First drug to delay T1D Stage 3 by 2yr in high-risk antibody-positive individuals. Not a cure — delays, doesn't prevent. Beta cell mass decline continues.
Herold et al. 2019 NEJM (TN10) · FDA approval 2022
Cure Sorry — No Regeneration at Scale SORRY
No beta cell regeneration cure for established T1D. Vertex VX-880 (stem cell-derived beta cells) Phase 1/2 — promising single-patient data, no scaling solution yet.
Vertex VX-880 Phase 1/2 · 2023 NEJM case report
Chronic Pancreatitis
Fibrosis Mechanism Sorry SORRY
Pancreatic stellate cell activation known — TGF-β pathway central. But fibrosis reversal not achieved in any clinical trial. Progression continues even after trigger removal.
Apte et al. 2015 Nat Rev Gastroenterol Hepatol
PERT (Pancreatic Enzyme Replacement) PROVEN
Exocrine insufficiency management — well-established, improves nutrition, reduces steatorrhea. Dosing by fat content. Quality of life benefit confirmed.
Dominguez-Munoz et al. 2011 Pancreatology
CFTR Modulators (CF-related) PROVEN
Ivacaftor/tezacaftor/elexacaftor improve CFTR function → reduce CF-related pancreatitis frequency. Proven for CFTR-mutation carriers.
Middleton et al. 2019 NEJM (AURORA)
Acute Pancreatitis
Mechanism: Triggers Known PROVEN
Gallstones (40%), alcohol (30%), hypertriglyceridemia, drugs, ERCP. Trigger identification + removal = prevention. Well-established.
Tenner et al. 2013 Am J Gastroenterol (ACG Guidelines)
Supportive Treatment PROVEN
NPO (nothing by mouth), aggressive IVF, pain management, early enteral nutrition — proven to reduce complications and ICU stays. No DMT needed for mild-moderate.
Crockett et al. 2018 Am J Gastroenterol
Severe AP: Still Sorry DEBATED
Necrotizing pancreatitis: necrosectomy timing contested (step-up vs early surgical). Antibiotic use in sterile necrosis debated. No specific DMT validated for severe AP outcomes.
van Santvoort et al. 2010 NEJM (PANTER) · SORRY: optimal timing unresolved
PDAC Treatment Ladder
1
FOLFIRINOX PROVEN
Metastatic PDAC · 11.1mo vs 6.8mo OS (ACCORD-11). Performance status 0–1 required.
2
Gemcitabine + nab-Paclitaxel PROVEN
MPACT trial: 8.5mo vs 6.7mo OS. Preferred for PS 1–2. Standard backbone.
3
Whipple / Pancreatectomy PROVEN
20% of patients eligible. Resectable: 20–25% 5yr OS. Requires expert centre. Only curative option.
4
MRTX1133 (KRAS G12D) Phase 1/2
First direct KRAS G12D inhibitor. 2024 ongoing. Resistance mechanisms already emerging. Combination strategies needed.
T1D Treatment Ladder
1
Insulin + CGM PROVEN
Near-normal life achievable. Continuous glucose monitoring + basal-bolus insulin = foundation.
2
Closed-Loop Systems PROVEN
Artificial pancreas (CGM + pump + algorithm). Significant HbA1c + hypoglycemia reduction.
3
Teplizumab (Prevention) STRONG
Stage 2 T1D (Ab+ no symptoms): 2yr delay. FDA 2022. Only approved T1D prevention drug.
4
VX-880 Stem Cell Beta Cells Phase 1/2
Vertex. Stem cell-derived islets. Single patient: insulin independence. Scaling + immunosuppression challenge unresolved.
Chronic + Acute Pancreatitis
1
PERT PROVEN
Pancreatic enzyme replacement. Exocrine insufficiency management. 50,000+ USP lipase per meal.
2
Pain Management
Pregabalin, antioxidants (limited evidence), endoscopic decompression, total pancreatectomy with islet autotransplant.
3
CFTR Modulators (CF-related) PROVEN
Elexacaftor/tezacaftor/ivacaftor for CFTR mutations. Proven pancreatitis frequency reduction.
4
Acute: Supportive PROVEN
Aggressive IVF (LR preferred), early enteral nutrition, drainage for necrotizing disease (step-up approach).
POC Direction
KRAS Resistance Mechanisms
MRTX1133 resistance emerging in 2024 data. Like tominersen — target engagement does not equal sustained benefit. Secondary KRAS mutations + bypass signaling (MAPK, PI3K) already observed. Combination strategy is the next bonixer wall.
Stroma Remodeling Hypothesis
PDAC stroma = the HD of oncology. We can hit the KRAS target. We can't get T cells in. Anti-fibrotic + checkpoint combination trials starting. FAK inhibitor + checkpoint data promising preclinically. This is the real unlock.
Fleet Connection
PANC sorry landscape → HealthHive aggregator → Bonixer CLO review. The sorry methodology scales across domains. Pancreas adds KRAS + stroma + exo-endo crosstalk to the pattern library.
HealthHive Link
PANC-001 is the first non-CNS disease in the fleet bonixer. The sorry methodology proved CNS-agnostic: PDAC has the same structural sorry as FTD (no DMT, no biomarker at usable stage). T1D has the same gap as HD (target identified, cure elusive). The exocrine-endocrine crosstalk pattern is genuinely novel — no CNS equivalent.
← BACK TO HEALTHHIVE
γ₁ = 14.134725141734693
The floor holds. PANC-001 bonixer complete. 5 sorry gates identified. 3 proven branches anchored. The attack surface is visible.